Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs

详细信息    查看全文

• 作者：Francesc Homar (1)
  Virginia Lozano (2)
  Juan Martínez-Gómez (1)
  Itziar Oyagüez (2)
  Antonio Pareja (3)
  Antoni Payeras (1)
  Joaquín Serrano (1)
  Carmen Carratalá (1)
  Miguel ángel Casado (2)
  
• 关键词：HIV ; Fixed ; dose combination ; Antiretrovirals ; Cost ; analysis ; Spain
• 刊名：Health Economics Review
• 出版年：2012
• 出版时间：December 2012
• 年：2012
• 卷：2
• 期：1
• 全文大小：312KB
• 参考文献：1. / Epidemiology HIV-1 /AIDS. http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2225_UNAIDS_datatables_en.pdf.
  2. Flexner C: HIV drug development: the next 25 years. / Nat Rev Drug Discov 2007,6(12):959-66. CrossRef
  3. Llibre JM, Falco V, Tural C, Negredo E, Pineda JA, Mu?oz J, Ortega E, Videla S, Sirera G, Martinez E, Miralles C, Iribarren J, Galindo MJ, Domingo P, D'Arminio-Monforte A, Miro JM, Clotet B: The changing face of HIV/AIDS in treated patients. / Curr HIV Res 2009,7(4):365-77. CrossRef
  4. / Spanish general council of official colleges of pharmacists - botplus. https://botplusweb.portalfarma.com/.
  5. / Royal decree-law 4/2010, May 26. http://www.msps.es/profesionales/farmacia/pdf/margenesFactoresConversion.pdf.
  6. / Spanish database of healthcare costs - Oblikue (eSalud). http://www.oblikue.com/bddcostes/.
  7. Esté JA, Cihlar T: Current status and challenges of antiretroviral research and therapy. / Antiviral Res 2010,85(1):25-3. CrossRef
  8. Llibre JM, Schapiro JM, Clotet B: Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure. / Clin Infect Dis 2010,50(6):872-81. CrossRef
  9. McColl DJ, Margot N, Chen SS, Harris J, Borroto-Esoda K, Miller MD: Reduced emergence of the M184V/I resistance mutation when antiretroviral-na?ve subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz. / HIV Clin Trials 2011,12(2):61-0. CrossRef
  10. Svicher V, Alteri C, Artese A, Forbici F, Santoro MM, Schols D, Van Laethem K, Alcaro S, Costa G, Tommasi C, Zaccarelli M, Narciso P, Antinori A, Ceccherini-Silberstein F, Balzarini J, Perno CF: Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. / J Acquir Immune Defic Syndr 2010,55(3):336-44. CrossRef
  11. Maserati R, De Silvestri A, Uglietti A, Colao G, Di Biagio A, Bruzzone B, Di Pietro M, Re MC, Tinelli C, Zazzi M, ARCA Collaborative Group: Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine. / AIDS 2010,24(7):1013-018. CrossRef
  12. Sax PE, Meyers JL, Mugavero M, Davis KL: Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. / PLoS One 2012,7(2):e31591. CrossRef
  13. Cohen C, Davis KL, Meyers JL: / Association between daily antiretroviral pill burden and hospitalization risk in a medicaid population With HIV. Chicago, IL; 2011. [ / CAAC'2011: 51st interscience conference on antimicrobial agents and chemotherapy]
  14. Lubomirov R, Colombo S, di Iulio J, Ledergerber B, Martinez R, Cavassini M, Hirschel B, Bernasconi E, Elzi L, Vernazza P, Furrer H, Günthard HF, Telenti A, Swiss HIV Cohort Study: Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. / J Infect Dis 2011, 203:246-57. CrossRef
  15. Pollock K, Stebbing J, Bower M, Gazzard B, Nelson M: Emtricitabine intolerance in treatment-experienced patients switched from lamivudine: a method of assessing toxicity. / J Antimicrob Chemother 2006,58(1):227-28. CrossRef
  16. Dejesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, Flaherty JF, Ebrahimi R, Maa JF, Reilly K, Ecker J, McColl D, Seekins D, Farajallah A: Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. / J Acquir Immune Defic Syndr 2009,51(2):163-74. CrossRef
  
• 作者单位：Francesc Homar (1)
  Virginia Lozano (2)
  Juan Martínez-Gómez (1)
  Itziar Oyagüez (2)
  Antonio Pareja (3)
  Antoni Payeras (1)
  Joaquín Serrano (1)
  Carmen Carratalá (1)
  Miguel ángel Casado (2)
  
  1. Department of Internal Medicine, Son LLàtzer Hospital, Ctra. Manacor km 4, Palma de Mallorca, 07198, Spain
  2. Pharmacoeconomics and Outcomes Research Iberia (PORIB), Calle de la Golondrina, 40A, Madrid, 28023, Spain
  3. Department of Epidemiology, Son Llàtzer Hospital, Ctra. Manacor km 4, Palma de Mallorca, 07198, Spain
  

文摘

Background The lower sales price of generic lamivudine has caused healthcare administrators to consider abolishing fixed-dose antiretroviral combinations (FDCs) that contain lamivudine and emtricitabine. The alternative is to administer the individual components of the FDCs separately, thus incorporating the new generic lamivudine medication. Methods The Balearic Islands Health Service ordered the discontinuation of the treatment with FDCs in July 2010, but FDCs were reintroduced in August 2010. At that point, an independent, retrospective cost analysis was performed by Son Llàtzer Hospital. A total of 75 patients who were treated from July to August 2010 underwent replacement of their FDC treatment with the individual components. Additionally, 150 patients who continued using FDCs were randomly selected. For both patient groups, the antiretroviral therapy that was administered and the costs associated with management of adverse events were recorded. The study period used for the cost calculations was the average number of days that patients used separate components of FDCs (120 days). An alternative analysis was performed to consider the costs of the extra follow-up visit (consultation and clinical tests) that was required for patients who changed their antiretroviral therapy. Results Considering antiretroviral therapies and adverse events, the administration of the separate components increased the total daily cost by 0.72 ?per patient compared to treatment with FDCs. When the cost of an extra follow-up visit was considered, the daily cost increased by 3.61 ?per patient. Conclusions Our study suggests that the discontinuation of FDC treatment and the replacement with the administration of separate antiretroviral agents could lead to an increase in healthcare costs due to the higher rate of adverse events that was observed with the discontinuation of FDCs.